Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Rejected. The original entry is no longer available at $46.71. Do not chase; rebuild the setup after a new base.
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
| Metric | Value | Signal |
|---|---|---|
| Revenue (TTM) | EUR 32.6M | 0.0% YoY |
| EBITDA | N/A | Not meaningful / unavailable |
| Gross Margin | 100.0% | Reported |
| Operating Margin | -196.4% | Loss-making |
| Net Margin | -73.5% | Negative |
| ROE | 0.0% | Capital efficiency |
| Cash | EUR 52.8M | Liquidity |
| Debt | EUR 95.3M | Balance-sheet claim |
| Forward P/E | N/A | No estimate substituted |
| Intrinsic-value model | N/A | Fail-closed: insufficient inputs |
| Value / quality panel | 0 positive / 5 negative / 0 neutral | bearish / confidence 52 |
| Analyst Mean Target | $45.47 | Consensus, not a guarantee |
No structured transaction table was captured; aggregate counts are not used.
The 2026 offering raised EUR85M gross through 2.185M shares and 345,099 pre-funded warrants, about 5% immediate dilution. A $200M shelf and 5.624M JJDC resale shares are also registered.
Official filings were reviewed through 2026-08-28; the table lists the decision-relevant documents rather than every routine filing. The C- grade describes the full dossier; the trade state (missed) is a separate timing decision.
| Date | Form | Accession | What the filing changes |
|---|---|---|---|
| 2026-05-22 | 424B5 | 0001140361-26-022604 | Final terms for the equity and pre-funded-warrant offering. |
| 2025-03-06 | F-3 | 0001140361-25-007433 | Establishes the $200M shelf and JJDC resale registration. |
Current snapshot only; no acceleration claim without a comparable historical series.
Unusual Activity: No unusual activity confirmed
| RSI (14) | 60.1 |
| EMA 20 | $41.24 |
| EMA 50 | $39.67 |
| EMA 200 | $31.32 |
| MACD | 1.350 |
| Signal | 0.918 |
| ATR (14) | $3.08 |
| Wyckoff | Transitional |
Rejected. Required confirmation: Pull back, then reclaim $40.50. Available moving averages are shown with their provider type.
| Indicator | Value | Signal |
|---|---|---|
| Market regime | Risk-on 0.79 | Trend support, not a timing trigger |
| VIX | 14.51 | Low current protection price |
Regime: risk-on
The broad regime supports long setups, but rates and ticker-specific confirmation override the label.
Dilution: high; beta: 0.57; insider signal: unavailable.
A precise stop does not make a setup valid. Entry location, normal volatility, event risk and reachable resistance decide whether the risk is paid.
No directional flow claim is made when detailed, aligned flow data is unavailable.
Rejected. The original entry is no longer available at $46.71. Do not chase; rebuild the setup after a new base.
Wait for confirmation and preserve the invalidation.
This analysis is provided for informational and educational purposes only. It does not constitute financial advice, investment recommendation, or solicitation to buy or sell any security.
Past performance is not indicative of future results. All investments involve risk, including the possible loss of principal. Always conduct your own research and consult a licensed financial advisor before making investment decisions.
Data comes from point-in-time market snapshots, company filings, Yahoo Finance, SEC EDGAR, and public market data. Accuracy is not guaranteed.
Social Radar
Pump & Dump Score: 3/6
Suspect